{
  "id": "3cf83f997661be38",
  "title": "Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study for Colorectal Cancer of Biparatopic HER2 - targeting ADC JSKN003",
  "description": "20260214T144500Z",
  "content": "",
  "source": "manilatimes.net",
  "source_url": "https://www.manilatimes.net/2026/02/14/tmt-newswire/pr-newswire/alphamab-oncology-announces-the-first-patient-dosed-in-a-phase-iii-clinical-study-for-colorectal-cancer-of-biparatopic-her2-targeting-adc-jskn003/2278407",
  "published_at": "20260214T144500Z",
  "fetched_at": "2026-02-15T00:30:56.287245+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [],
  "location": "Philippines",
  "raw_data": {
    "url": "https://www.manilatimes.net/2026/02/14/tmt-newswire/pr-newswire/alphamab-oncology-announces-the-first-patient-dosed-in-a-phase-iii-clinical-study-for-colorectal-cancer-of-biparatopic-her2-targeting-adc-jskn003/2278407",
    "url_mobile": "https://www.manilatimes.net/2026/02/14/tmt-newswire/pr-newswire/alphamab-oncology-announces-the-first-patient-dosed-in-a-phase-iii-clinical-study-for-colorectal-cancer-of-biparatopic-her2-targeting-adc-jskn003/2278407/amp",
    "title": "Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study for Colorectal Cancer of Biparatopic HER2 - targeting ADC JSKN003",
    "seendate": "20260214T144500Z",
    "socialimage": "https://www.manilatimes.net/theme_manilatimes/images/TMT_1920x1008.jpg",
    "domain": "manilatimes.net",
    "language": "English",
    "sourcecountry": "Philippines"
  }
}